- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
JCV Seroconversion in a Group of Iraqi Patients with Multiple Sclerosis Receiving Natalizumab | ||
| Al- Anbar Medical Journal | ||
| Volume 22, Issue 1, January 2026, Pages 22-26 PDF (356.11 K) | ||
| Document Type: Original articles | ||
| DOI: 10.33091/amj.2025.161470.2288 | ||
| Authors | ||
| Ahmed Ali Hussein* 1; Sajid Ibrahim Kadhim2 | ||
| 1Department of Internal Medicine/Neuromedicine, Ramadi Teaching Hospital, Anbar Health Directorate, Anbar Governorate, Iraq. | ||
| 2Department of Internal Medicine/Neuromedicine, Baghdad Teaching Hospital, Baghdad, Iraq. | ||
| Abstract | ||
| Background: Natalizumab is a well-established therapy for multiple sclerosis (MS) that carries a risk of progressive multifocal leukoencephalopathy (PML) linked to John Cunningham virus (JCV). While JCV seroconversion has been well studied in the western hemisphere, data from the Middle east, including Iraq, are limited. Objective: To assess JCV seroconversion rates and associated risk factors among Iraqi MS patients treated with Natalizumab. Materials and Methods: a retrospective cohort study included patients with MS who were followed at the MS Clinic of Baghdad Medical City between January 2015 and December 2023. Data were collected from 290 patients and included demographics, treatment duration, prior exposure to other disease-modifying therapies (DMTs), and JCV antibody index values. The JCV antibody status was assessed every six months using a two-step enzyme-linked immunosorbent assay (ELISA). Results: In this sample, 18% (n = 52) exhibited persistent JCV seroconversion, corresponding to an annual conversion rate of 5.2%. The seroconversion rate was 25.4% in males and 15.5% in females; which was just short of reaching statistical significance (P-value = 0.06). No significant association was observed between seroconversion and age, treatment duration, or prior exposure to DMTs (P-value > 0.05). Notably, the highest seroconversion rate (20%) was observed in patients who had previously received treatment with interferon-β derivatives. Importantly, no cases of PML were identified during the study period. Conclusion: JCV seroconversion in Iraqi patients on natalizumab was 18% (annual 5.2%), with no significant risk factors identified. JCV monitoring remains crucial, and no cases of PML were detected. | ||
| Keywords | ||
| JCV seroconversion; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy | ||
| References | ||
|
[1] B. A. Cree, J. R. Oksenberg, and S. L. Hauser, "Multiple sclerosis: two decades of progress," The Lancet Neurology, vol. 21, no. 3, pp. 211-214, 2022.
[2] G. Vivekanandan et al., "Risk of progressive multifocal leukoencephalopathy in multiple sclerosis patient treated with natalizumab: a systematic review," Cureus, vol. 13, no. 4, 2021.
[3] B. Hemmer et al., "Efficacy and safety of proposed biosimilar natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis: the Antelope phase 3 randomized clinical trial," JAMA neurology, vol. 80, no. 3, pp. 298-307, 2023.
[4] S. García et al., "Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment," Biomedicines, vol. 12, no. 12, p. 2737, 2024.
[5] K. Kapica-Topczewska et al., "John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis," European Neurology, vol. 83, no. 5, pp. 487-492, 2020.
[6] R. N. Yahya, A. A. Kasim, and G. A. Al Gawwam, "Comparing the quality of life among patients with relapsing remitting multiple sclerosis in Iraq using different disease modifying therapies," Iraqi Journal of Pharmaceutical Sciences, vol. 27, no. 2, pp. 102-114, 2018.
[7] R. Berkovich, J. Eskenazi, A. Yakupova, and E. L. Riddle, "Progressive multifocal leukoencephalopathy risk perception in patients considering natalizumab for multiple sclerosis," International Journal of MS Care, vol. 24, no. 1, pp. 13-17, 2022.
[8] J. Y. Mescheriakova et al., "Application of the 2017 revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome," JAMA neurology, vol. 75, no. 11, pp. 1392-1398, 2018.
[9] A. J. Thompson et al., "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria," The Lancet Neurology, vol. 17, no. 2, pp. 162-173, 2018.
[10] C. Prezioso et al., "Diagnostic value of JC polyomavirus viruria, viremia, serostatus and microRNA expression in multiple sclerosis patients undergoing immunosuppressive treatment," Journal of Clinical Medicine, vol. 11, no. 2, p. 347, 2022.
[11] C. Dwyer, S. Sharmin, and T. Kalincik, "Rates of John Cunningham virus seroconversion greatly reduced in natalizumab‐treated patients during COVID‐19‐related lockdowns," European Journal of Neurology, vol. 31, no. 1, p. e16059, 2024.
[12] E. Sgarlata, C. G. Chisari, E. D’Amico, E. Millefiorini, and F. Patti, "Changes in anti-JCV antibody status in a large population of multiple sclerosis patients treated with natalizumab," CNS drugs, vol. 34, no. 5, pp. 535-543, 2020.
[13] A. Azimi, S. Hanaei, M. A. Sahraian, M. Mohammadifar, S. V. Ramagopalan, and M. Ghajarzadeh, "Incidence of seroconversion and sero-reversion in patients with multiple sclerosis (MS) who had been treated with natalizumab: A systematic review and meta-analysis," Journal of Clinical Neuroscience, vol. 71, pp. 129-134, 2020.
[14] D. Fairweather, D. J. Beetler, E. J. McCabe, and S. M. Lieberman, "Mechanisms underlying sex differences in autoimmunity," The Journal of clinical investigation, vol. 134, no. 18, 2024.
[15] T. Glenn, J. R. Berger, and C. R. McEntire, "Natalizumab-associated progressive multifocal leukoencephalopathy," Frontiers in Neurology, vol. 16, p. 1575653, 2025.
[16] M. J. Sá, C. C. Nunes, A. M. da Silva, P. Mota, J. Pinto-Marques, and J. Investigators, "JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results," Journal of the Neurological Sciences, vol. 406, p. 116426, 2019.
[17] H. Butzkueven et al., "Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)," Journal of Neurology, Neurosurgery & Psychiatry, vol. 91, no. 6, pp. 660-668, 2020.
[18] S. O'Leary et al., "Practical clinical guidelines for natalizumab treatment in patients with relapsing multiple sclerosis," Journal of Infusion Nursing, vol. 46, no. 6, pp. 347-359, 2023.
[19] L. M. Gelissen et al., "Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis," Journal of Neurology, Neurosurgery & Psychiatry, 0:1–8, 2025.
[20] L. P. Branco et al., "Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis," Arquivos de Neuro-Psiquiatria, vol. 76, no. 09, pp. 588-591, 2018.
[21] T. Rempe, A. Carlson, A. Miravalle, and T. V. Gyang, "Anti-JCV antibody index does not change during ocrelizumab-treatment," Multiple Sclerosis Journal–Experimental, Translational and Clinical, vol. 6, no. 3, p. 2055217320960510, 2020.
[22] L. M. Villar et al., "Immunological markers of optimal response to natalizumab in multiple sclerosis," Archives of neurology, vol. 69, no. 2, pp. 191-197, 2012.
| ||
|
Statistics Article View: 464 PDF Download: 210 |
||